Calum Jones, Senior Consultant – Health Economics at Mtech Access, held a conversation with Dr. George Magrath, CEO at Lexitas, on the current and future use of artificial intelligence (AI) in clinical trials. The discussion included the acceptance of AI-generated evidence and its implications on evidence synthesis and market access.
The dialogue delved into how AI is currently used in the development of new medicines and clinical trials. It explored the areas where AI could bridge gaps and solve challenges, and what this could mean for the future of market access.
Dr. George Magrath elucidated how his team at Lexitas uses AI in clinical trials in the field of ophthalmology. The discussion covered the usage of AI in clinical trials, its potential solutions to existing obstacles in clinical trials and ophthalmic drug development, the future of AI in the development of new medicines, and the role of AI in selecting patients for clinical trials.
In addition, the conversation addressed the impact AI may have on the evaluation of drug effectiveness and what this means for evidence synthesis, health economics, reimbursement, and market access. The future prospects of AI in pharmaceutical development were also part of the dialogue.
The webinar included an introduction to Dr. George Magrath, a trained ophthalmologist, and CEO of Lexitas, a company of 160 people that collaborates with pharmaceutical companies to develop novel eye care drugs by conducting clinical trials.
The webinar is part of the Global Whispers series, which examines global market access trends and challenges facing the Pharmaceutical and Medtech industries and offers insights into key launch markets.
The conversation highlighted the extent of Mtech Access’s expertise in the fields of health economics and outcomes research (HEOR), evidence synthesis, and global market access.
The utilization of AI in clinical trials can potentially revolutionize the entire process, from patient selection to the evaluation of drug effectiveness. Its influence on evidence synthesis, health economics, reimbursement, and market access could also redefine the norms of pharmaceutical development, making the field more efficient and reliable.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
